drugset / Trial / NCT00715078
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
Timeline
- Start
- 2008-10
- Primary completion
- 2012-04
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sipuleucel-T | Cell therapy | 2 ug/ml | Other |
| Comparator | Sipuleucel-T | Cell therapy | 5 ug/ml | Other |
| Comparator | Sipuleucel-T | Cell therapy | 10 ug/ml | Other |